PriceTargets.com logo

Novo Nordisk A/S - NVO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $150.40
  • Forecasted Upside: 76.94%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$85.00 As of 12/20/2024 06:45 PM ET
▼ -18.44 (-17.83%)

This chart shows the closing price for NVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novo Nordisk A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVO

Analyst Price Target is $150.40
▲ +76.94% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Novo Nordisk A/S in the last 3 months. The average price target is $150.40, with a high forecast of $160.00 and a low forecast of $120.00. The average price target represents a 76.94% upside from the last price of $85.00.

This chart shows the closing price for NVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Novo Nordisk A/S. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/2/2024BNP ParibasUpgradeStrong-Buy
11/6/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
10/17/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$160.00 ➝ $156.00
10/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
8/19/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
8/8/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$170.00 ➝ $160.00
8/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
7/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
6/25/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$163.00 ➝ $163.00
6/17/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
6/10/2024ArgusBoost TargetBuy ➝ Buy$125.00 ➝ $160.00
5/30/2024The Goldman Sachs GroupInitiated CoverageBuy$156.00
4/18/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
4/12/2024BMO Capital MarketsInitiated CoverageOutperform$163.00
4/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
3/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
2/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00
2/14/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00
2/1/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$120.00 ➝ $140.00
1/23/2024Morgan StanleyInitiated CoverageOverweight$120.00
1/16/2024UBS GroupInitiated CoverageNeutral
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
12/18/2023Cantor FitzgeraldReiterated RatingOverweight
12/4/2023TD CowenBoost TargetOutperform ➝ Outperform$105.00 ➝ $115.00
12/1/2023Cantor FitzgeraldInitiated CoverageOverweight$120.00
10/2/2023ArgusInitiated CoverageBuy$110.00
8/11/2023DNB MarketsDowngradeBuy ➝ Hold
7/14/2023HSBCInitiated CoverageBuy
4/13/2023Credit Suisse GroupUpgradeNeutral ➝ Outperform
12/12/2022CowenBoost Target$32.50 ➝ $36.25
12/12/2022CowenBoost Target$32.50 ➝ $36.25
11/4/2022Credit Suisse GroupBoost Target205.00 ➝ 215.00
9/29/2022Oddo BhfUpgradeNeutral ➝ Outperform
7/15/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight
6/28/2022UBS GroupDowngradeNeutral ➝ Sell
6/7/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
5/31/2022GuggenheimUpgradeNeutral ➝ Buy
5/5/2022Bryan, Garnier & CoUpgradeSell ➝ Neutral
5/4/2022Deutsche Bank AktiengesellschaftBoost Target212.50 ➝ 225.00
4/25/2022CowenUpgradeMarket Perform ➝ Outperform$32.50
4/25/2022CowenUpgradeMarket Perform ➝ Outperform
4/19/2022Berenberg BankBoost TargetHold ➝ Hold146.25 ➝ 195.00
4/12/2022Morgan StanleyUpgradeUnderweight ➝ Equal Weight
3/16/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
3/2/2022CitigroupUpgradeNeutral ➝ Buy
3/1/2022Berenberg BankBoost TargetHold ➝ Hold132.50 ➝ 146.25
2/28/2022Stifel NicolausInitiated CoverageBuy
2/3/2022DanskeUpgradeHold ➝ Buy
1/25/2022Liberum CapitalDowngradeHold ➝ Sell
12/20/2021CitigroupDowngradeBuy ➝ Neutral
12/20/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
12/20/2021DanskeDowngradeBuy ➝ Hold
12/17/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
11/11/2021UBS GroupReiterated RatingNeutral
11/4/2021BarclaysReiterated RatingOverweight
11/4/2021Credit Suisse GroupReiterated RatingNeutral
11/4/2021JPMorgan Chase & Co.Reiterated RatingOverweight
11/3/2021Bryan, Garnier & CoDowngradeBuy ➝ Sell148.00
11/2/2021Morgan StanleyReiterated RatingUnderweight
11/1/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
10/29/2021DNB MarketsDowngradeBuy ➝ Hold
10/18/2021SEB EquitiesUpgradeHold ➝ Buy
9/3/2021Berenberg BankReiterated RatingHold
8/23/2021Credit Suisse GroupReiterated RatingNeutral
8/23/2021CitigroupReiterated RatingBuy
8/17/2021UBS GroupReiterated RatingNeutral
8/11/2021Morgan StanleyReiterated RatingUnderweight
8/6/2021JPMorgan Chase & Co.Reiterated RatingOverweight
8/5/2021BarclaysReiterated RatingOverweight
8/5/2021Bank of AmericaUpgradeNeutral ➝ Buy
8/5/2021DNB MarketsUpgradeHold ➝ Buy
8/3/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
7/19/2021BarclaysReiterated RatingOverweight
7/15/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
2/11/2021UBS GroupReiterated RatingNeutral
2/4/2021BarclaysReiterated RatingOverweight
1/20/2021Credit Suisse GroupDowngradeOutperform ➝ Neutral
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuy
11/12/2020JPMorgan Chase & Co.Reiterated RatingOverweight
11/6/2020Morgan StanleyDowngradeEqual Weight ➝ Underweight
11/3/2020Societe GeneraleReiterated RatingSell
10/15/2020Morgan StanleyReiterated RatingEqual Weight
9/29/2020Berenberg BankInitiated CoverageHold
8/18/2020UBS GroupReiterated RatingNeutral
8/3/2020Morgan StanleyReiterated RatingEqual Weight
7/6/2020Bank of AmericaDowngradeBuy ➝ Neutral
5/18/2020Morgan StanleyReiterated RatingEqual Weight
5/13/2020JPMorgan Chase & Co.Reiterated RatingOverweight
5/11/2020UBS GroupDowngradeBuy ➝ Neutral
5/7/2020Societe GeneraleReiterated RatingSell
5/4/2020CowenInitiated CoverageMarket Perform$18.00
3/23/2020UBS GroupUpgradeNeutral ➝ Buy
3/16/2020Bank of AmericaUpgradeNeutral ➝ Buy
1/3/2020GuggenheimDowngradeBuy ➝ Neutral
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 72 very positive mentions
  • 45 positive mentions
  • 20 negative mentions
  • 5 very negative mentions
Mentions as of
5/25/2024
  • 49 very positive mentions
  • 19 positive mentions
  • 8 negative mentions
  • 1 very negative mentions
Mentions as of
6/24/2024
  • 52 very positive mentions
  • 37 positive mentions
  • 12 negative mentions
  • 2 very negative mentions
Mentions as of
7/24/2024
  • 51 very positive mentions
  • 40 positive mentions
  • 18 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 50 very positive mentions
  • 39 positive mentions
  • 9 negative mentions
  • 1 very negative mentions
Mentions as of
9/22/2024
  • 58 very positive mentions
  • 43 positive mentions
  • 14 negative mentions
  • 4 very negative mentions
Mentions as of
10/22/2024
  • 84 very positive mentions
  • 63 positive mentions
  • 10 negative mentions
  • 3 very negative mentions
Mentions as of
11/21/2024
  • 104 very positive mentions
  • 53 positive mentions
  • 20 negative mentions
  • 2 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 104 very positive mentions
  • 53 positive mentions
  • 20 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Novo Nordisk A/S logo
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Read More

Today's Range

Now: $85.00
Low: $81.50
High: $86.53

50 Day Range

MA: $109.01
Low: $85.00
High: $119.77

52 Week Range

Now: $85.00
Low: $81.50
High: $148.15

Volume

53,564,469 shs

Average Volume

4,737,458 shs

Market Capitalization

$381.44 billion

P/E Ratio

27.51

Dividend Yield

0.68%

Beta

0.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Novo Nordisk A/S?

The following Wall Street analysts have issued stock ratings on Novo Nordisk A/S in the last year: Argus, BMO Capital Markets, BNP Paribas, Cantor Fitzgerald, Morgan Stanley, StockNews.com, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for NVO.

What is the current price target for Novo Nordisk A/S?

0 Wall Street analysts have set twelve-month price targets for Novo Nordisk A/S in the last year. Their average twelve-month price target is $150.40, suggesting a possible upside of 76.9%. Argus has the highest price target set, predicting NVO will reach $160.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $120.00 for Novo Nordisk A/S in the next year.
View the latest price targets for NVO.

What is the current consensus analyst rating for Novo Nordisk A/S?

Novo Nordisk A/S currently has 1 hold rating, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NVO will outperform the market and that investors should add to their positions of Novo Nordisk A/S.
View the latest ratings for NVO.

What other companies compete with Novo Nordisk A/S?

Other companies that are similar to Novo Nordisk A/S include AstraZeneca, Novartis, Sanofi, GSK and Takeda Pharmaceutical. Learn More about companies similar to Novo Nordisk A/S.

How do I contact Novo Nordisk A/S's investor relations team?

Novo Nordisk A/S's physical mailing address is Novo Alle, Bagsvaerd G7, 2880. The company's listed phone number is (454) 444-8888 and its investor relations email address is [email protected]. The official website for Novo Nordisk A/S is www.novonordisk.com. Learn More about contacing Novo Nordisk A/S investor relations.